| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 1, 2021 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 1, 2021 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/8/2021 | $22.00 | Neutral → Buy | HC Wainwright & Co. |
Ended second quarter 2021 with $36.8 million in cash and cash equivalents On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., which is subject to the approval of Aerpio shareholders and other customary closing conditions CINCINNATI, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO), a biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2021 and provided a business update. Key Business Update: On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., a Delaware company ("Aadi"), and Aspen Merger Subsidiary, Inc., a D
CINCINNATI, June 04, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience, Inc. (“Aadi”), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today issued a press release disclosing that a poster has been presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. As previously disclosed, on May 16, 2021, Aerpio entered into an Agreement and Plan of Merger among Aerpio, Aadi, and Aspen Merger Subsidiary, Inc. About Aerpio Pharmaceuticals Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on develo
CINCINNATI, May 19, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO) announced that Aadi Bioscience ("Aadi"), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today issued a press release disclosing its abstract to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. As previously disclosed, on May 16, 2021, Aerpio entered into an Agreement and Plan of Merger among Aerpio, Aadi, and Aspen Merger Subsidiary, Inc. About Aerpio Pharmaceuticals Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compound
EFFECT - Aadi Bioscience, Inc. (0001422142) (Filer)
S-8 - Aadi Bioscience, Inc. (0001422142) (Filer)
S-3 - Aadi Bioscience, Inc. (0001422142) (Filer)
HC Wainwright & Co. upgraded Aerpio Pharmaceuticals from Neutral to Buy and set a new price target of $22.00
HC Wainwright resumed coverage of Aerpio Pharmaceuticals with a rating of Hold
SC 13D - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13D - Aadi Bioscience, Inc. (0001422142) (Subject)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
3 - Aadi Bioscience, Inc. (0001422142) (Issuer)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
CINCINNATI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company’s clinical assets and cash resources, which amounted to $47.3 million as of September 30, 2020. As part of this process, the Company will explore strategic options for partnering its programs, as well as, the potential for an acquisition, company sale, merger, business combination, asset sale, in-license, out-licens